A $3 Billion Startup ' s Shares Gain On Hopes For A Cancer Blood Test

Shares in Guardant Health, which makes blood tests that can be used to detect mutations in cancer tumors, have doubled from the $19 price set in the company ’s October 4 initial public offering.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news